Compare Biogen Inc (BIIB) vs Harmony Gold Mining Co. (HMY) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Harmony Gold Mining (HMY) trades at $14.99, down 0.79% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with 2024 revenue of $61.38 billion and net income of $8.59 billion, yielding robust profitability margins. Recent earnings were mixed, beating in Q2 2025 but missing in Q4 2025. Analyst sentiment is cautious with 70% hold ratings, while news highlights stock volatility tied to gold price sensitivity and Fed policy expectations.

HMY presents a valuation opportunity with low P/E (9.59) and EV/EBITDA (5.05) multiples, supported by high ROE (32.32%) and a 4.06% dividend yield. Key risks include gold price exposure, operational execution in its pivot to gold-copper hybrid model, and macroeconomic headwinds from potential interest rate hikes. Institutional consensus leans neutral, suggesting patience for copper project contributions to justify higher multiples.